The short version
Scenesse is the specific approved implant, intended to increase pain-free light exposure in adults with erythropoietic protoporphyria. The selected exploratory study below concerns a different question: short-term UV responses in healthy volunteers.
Prescription status is product-specific. A recognized ingredient name does not make every preparation equivalent.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Melanotan-1
- Entry name · The name used for this encyclopedia topic.
- Melanotan 1
- Recorded name variation · A name associated with this entry; check exact ingredient, modification, formulation and context.
- Afamelanotide
- Drug name · Name used in the cited Scenesse label.
- Scenesse
- Approved product name · Specific implant; not a synonym for every Melanotan I preparation.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
What does this source leave unanswered?
The small implant study does not validate online tanning preparations, sun protection claims or other routes.
Limits of the selected research · Selected original research abstract ↗
Does approval mean a tanning vial is equivalent?
No. The cited approval concerns a specific implant and indication. A different preparation, route or purpose needs separate evidence.
Product-specific approval · FDA · Scenesse prescribing information ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Delivery methods
How a compound is delivered can change the question being studied. These selected examples explain the route, purpose and evidence limits; they do not establish an appropriate route for an individual.
Subcutaneous afamelanotide implant
Human research; exploratory before-and-after uv-response study
- Why it was studied or discussed
- The route used in this selected study; this is research context, not instructions.
- What this means for the reader
- The small implant study does not validate online tanning preparations, sun protection claims or other routes.
This is a selected comparison, not an exhaustive list of preparations or a guide to administering them. The clinical summaries below identify the route used in each study.
Clinical research
A selected human study is summarized below. Its design and preparation limit what can be inferred.
Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.
Summary based on: Published abstract, retrieved through Europe PMC; full text not appraised
- Study design
- Exploratory before-and-after UV-response study
- Who was studied
- Nine healthy adults
- Route and preparation
- Subcutaneous afamelanotide implant
- What was compared
- Measurements before and six days after implantation; no parallel placebo group
- What researchers found
- A nine-person exploratory study used an afamelanotide implant and measured short-term pigmentation and ultraviolet-response changes.
- What this leaves unanswered
- The small implant study does not validate online tanning preparations, sun protection claims or other routes.
Research terms in everyday language ↗
This overview covers the selected published abstract, retrieved through Europe PMC. Full-text appraisal and a comprehensive literature review are not complete; omitted studies are a coverage gap, not evidence that they do not exist.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- A melanocortin-related peptide name associated with afamelanotide; the precise medicinal product matters.
- Name variations
- Names you may see and important distinctions
- Source type
- US product label and selected research abstract
- Reference jurisdiction
- United States · approved-product context
A receptor is a structure that receives a chemical signal. An agonist activates a receptor. The mechanism section of the linked label explains the relevant pathway in greater detail.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗